CHICAGO, March 28, 2025--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range ...

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal radiologic exams, expanding the product's sales base beyond diabetic ...

Xeris Biopharma Trading Down 1.6 % Shares of XERS opened at $5.49 on Tuesday. The stock has a market cap of $845.13 million, a PE ratio of -12.20 and a beta of 2.32. Xeris Biopharma Holdings, Inc ...

Xeris Biopharma (XERS) shares ended the last trading session 5.6% higher at $5.51. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Xeris Biopharma Price Performance Shares of XERS stock opened at $5.58 on Friday. The company has a market cap of $858.99 million, a price-to-earnings ratio of -12.40 and a beta of 2.32. Xeris ...

ByInvesting.com • Feb 12, 2019 FDA accepts Xeris Pharma's application for glucagon rescue pen, action date June 10, 2019 The FDA accepts for review Xeris Pharmaceuticals ' (XERS -0.3% ...

Xeris Biopharma (XERS), a fast-growing biopharmaceutical company, beat top and bottom-line expectations for Q4 and announced it is expecting over 30% revenue growth in 2025. The company ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range ...